Industry News

Note: The following is edited from a press release from Bioverativ. Read the full press release in its entirety here.

Bioverativ Inc.,聽a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced findings from a novel imaging study investigating extravascular distribution of factor IX therapies, including its leading extended half-life therapy, ALPROLIX聽[Antihemophilic Factor IX (Recombinant), Fc Fusion Protein]. The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when compared with conventional factor IX and a glycoPEGylated factor IX analog. The study was conducted in collaboration with Invicro, LLC, a leading imaging services provider, and is being presented Dec. 9, 2017 at the 59th聽Annual Meeting of the American Society of Hematology.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.